Krystal Biotech Inc (KRYS) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Krystal Biotech Inc stock (KRYS) is currently trading at $254.95. Krystal Biotech Inc PE ratio is 36.12. Krystal Biotech Inc PS ratio (Price-to-Sales) is 18.56. Analyst consensus price target for KRYS is $314.00. WallStSmart rates KRYS as Hold.
- KRYS PE ratio analysis and historical PE chart
- KRYS PS ratio (Price-to-Sales) history and trend
- KRYS intrinsic value — DCF, Graham Number, EPV models
- KRYS stock price prediction 2025 2026 2027 2028 2029 2030
- KRYS fair value vs current price
- KRYS insider transactions and insider buying
- Is KRYS undervalued or overvalued?
- Krystal Biotech Inc financial analysis — revenue, earnings, cash flow
- KRYS Piotroski F-Score and Altman Z-Score
- KRYS analyst price target and Smart Rating
Krystal Biotech Inc
📊 No data available
Try selecting a different time range
KRYS Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Krystal Biotech Inc (KRYS)
KRYS trades 57% above its Graham fair value of $173.46, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Krystal Biotech Inc (KRYS) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in operating margin, profit margin, institutional own.. Concerns around price/sales and price/book. Fundamentals are solid but monitor weak areas for improvement.
Krystal Biotech Inc (KRYS) Key Strengths (5)
Keeps $41 of every $100 in revenue after operating costs
Keeps $53 of every $100 in revenue as net profit
99.40% of shares held by major funds and institutions
Mid-cap company balancing growth potential with stability
Solid profitability: $19 profit per $100 equity
Supporting Valuation Data
Krystal Biotech Inc (KRYS) Areas to Watch (4)
Very expensive at 18.6x annual revenue
Very expensive at 6.0x book value
Solid revenue growth at 17.50% per year
Solid earnings growth at 11.60%
Supporting Valuation Data
Krystal Biotech Inc (KRYS) Detailed Analysis Report
Overall Assessment
This company scores 57/100 in our Smart Analysis, earning a C grade. Out of 9 metrics analyzed, 5 register as strengths (avg 8.8/10) while 4 fall into concern territory (avg 4.0/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Operating Margin, Profit Margin, Institutional Own.. Profitability is solid with Return on Equity at 18.90%, Operating Margin at 41.30%, Profit Margin at 52.60%.
The Bear Case
The primary concerns are Price/Sales, Price/Book, Revenue Growth. Some valuation metrics including Price/Sales (18.56), Price/Book (6.03) suggest expensive pricing. Growth concerns include Revenue Growth at 17.50%, EPS Growth at 11.60%, which may limit upside.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Price/Sales improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 18.90% currently healthy but needing to be sustained. Third, growth sustainability, with Revenue Growth at 17.50% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. The weight of evidence leans positive, with more strengths than concerns. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (Operating Margin, Profit Margin) and negatives (Price/Sales, Price/Book). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
KRYS Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
KRYS's Price-to-Sales ratio of 18.56x trades at a deep discount to its historical average of 1206.72x (11th percentile). The current valuation is 99% below its historical high of 3595.53x set in Jul 2023, and 46% above its historical low of 12.67x in May 2025.
WallStSmart Analysis Synopsis
Data-driven financial summary for Krystal Biotech Inc (KRYS) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Krystal Biotech Inc is a strong growth company balancing expansion with improving profitability. Revenue reached 389M with 18% growth year-over-year. Profit margins are strong at 52.6%, reflecting pricing power and operational efficiency.
Key Findings
Profit margin of 52.6% and operating margin of 41.3% demonstrate strong pricing power and operational efficiency.
Generating 75M in free cash flow and 78M in operating cash flow. Earnings are translating into actual cash generation.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Krystal Biotech Inc.
Bottom Line
Krystal Biotech Inc offers an attractive blend of growth (18% revenue expansion) and improving fundamentals. The company is transitioning from pure growth to profitable growth, a critical inflection point. Watch for sustained margin expansion as the key signal.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(97 last 3 months)
| Insider | Type | Shares |
|---|---|---|
ROMANO, KATHRYN Chief Accounting Officer | Sell | -750 |
| Insider | Type | Shares |
|---|---|---|
JANNEY, DANIEL Director | Sell | -700 |
Data sourced from SEC Form 4 filings
Last updated: 4:27:18 PM
About Krystal Biotech Inc(KRYS)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Krystal Biotech, Inc., a clinical-stage biotechnology company, is dedicated to the field of redosable gene therapy to treat serious rare diseases in the United States. The company is headquartered in Pittsburgh, Pennsylvania.